Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Income (2023 - 2025)

Historic Operating Income for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Operating Income fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 2881.31%. This contributed to the annual value of -$56.6 million for FY2024, which is 1243.37% down from last year.
  • Latest data reveals that Compass Therapeutics reported Operating Income of -$15.8 million as of Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Operating Income ranged from a high of -$9.7 million in Q1 2023 and a low of -$21.1 million during Q2 2025
  • Its 3-year average for Operating Income is -$14.7 million, with a median of -$15.0 million in 2024.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 262.45% in 2024, then plummeted by 4068.91% in 2025.
  • Compass Therapeutics' Operating Income (Quarter) stood at -$15.4 million in 2023, then decreased by 7.67% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
  • Its Operating Income stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$18.0 million for Q1 2025.